Acquisition Opportunity Healix Infusion Therapy has been acquired by Singlepoint Healthcare as of June 16, 2026, signaling potential alignment with a broader infusion services platform. This presents a chance to engage through Singlepoint’s expanded network, explore integration of Healix’s infusion operations, and offer scalable software, hardware, and process improvements that support national coverage.

Infusion Network Growth Healix is described as a national infusion services provider supporting physician-owned and ambulatory infusion centers across the United States. This indicates a sizable market footprint and ongoing expansion opportunities with hospital systems, physician groups, and ambulatory centers seeking standardized workflows, compliance, and cost efficiency.

Technology & Workflow Past collaborations with WeInfuse and DoseMe plus a tech stack including Microsoft 365, Google Cloud, DocuSign, and enterprise software investments suggest openness to digital transformation. There is likely opportunity to upsell integrated workflow software, dosing decision support, and secure document management enhancements tailored to infusion centers.

Financial Scope Reported revenue in the range of one to ten million dollars with a relatively small employee base (11-50) indicates efficiency goals, scalability needs, and potential value propositions around cloud-based operations, automation, and cost containment that resonate with similar size care companies.

Partnership Potential Historical partnerships and strategic alignments with software and dosing platforms imply a favorable environment for cross-sell with healthcare IT vendors, pharmaceutical partners, and device suppliers. This could open doors for bundled offerings, preferred vendor agreements, and joint ventures to expand service capabilities.